Browsing: GLP1

The use of glucagon-like peptide-1 (GLP-1) receptor agonist medications continues to rise, with a 155% increase in the percentage of people with type 2 diabetes taking these drugs from 2018 to 2022

Commentary|Articles|January 28, 2026 Q&A: Why Dry January and GLP-1 Therapy May Be a Turning Point for Metabolic Health Author(s)David Shusterman, MD,Kennedy Ferruggia, Associate Editor Fact checked by:Ron Panarotti Listen